CN1654058A - Medicine for treating chronic kidney failure and its preparing process - Google Patents
Medicine for treating chronic kidney failure and its preparing process Download PDFInfo
- Publication number
- CN1654058A CN1654058A CN 200410039418 CN200410039418A CN1654058A CN 1654058 A CN1654058 A CN 1654058A CN 200410039418 CN200410039418 CN 200410039418 CN 200410039418 A CN200410039418 A CN 200410039418A CN 1654058 A CN1654058 A CN 1654058A
- Authority
- CN
- China
- Prior art keywords
- parts
- temperature
- relative densities
- minutes
- turn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000020832 chronic kidney disease Diseases 0.000 title claims abstract description 32
- 208000022831 chronic renal failure syndrome Diseases 0.000 title claims abstract description 32
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 229940079593 drug Drugs 0.000 title description 7
- 238000000034 method Methods 0.000 title description 7
- 230000008569 process Effects 0.000 title description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 64
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 239000000829 suppository Substances 0.000 claims abstract description 10
- 239000000706 filtrate Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 12
- 238000004064 recycling Methods 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 241000628997 Flos Species 0.000 claims description 9
- 238000005516 engineering process Methods 0.000 claims description 9
- 239000004698 Polyethylene Substances 0.000 claims description 6
- 241000545442 Radix Species 0.000 claims description 6
- 238000006073 displacement reaction Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- -1 polyethylene Polymers 0.000 claims description 6
- 229920000573 polyethylene Polymers 0.000 claims description 6
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 claims description 6
- 229940113116 polyethylene glycol 1000 Drugs 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- 238000010257 thawing Methods 0.000 claims description 6
- 239000009636 Huang Qi Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 6
- 210000000664 rectum Anatomy 0.000 abstract description 5
- 210000004185 liver Anatomy 0.000 abstract description 3
- 238000010579 first pass effect Methods 0.000 abstract description 2
- 230000002496 gastric effect Effects 0.000 abstract description 2
- 238000001914 filtration Methods 0.000 abstract 2
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 238000000465 moulding Methods 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 238000002791 soaking Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 15
- 230000006378 damage Effects 0.000 description 6
- 230000003907 kidney function Effects 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000001447 compensatory effect Effects 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 229940126701 oral medication Drugs 0.000 description 3
- 239000009457 shenkang Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000037157 Azotemia Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000000885 nephron Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000003623 Hypoalbuminemia Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000031816 Pathologic Dilatation Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to one kind of medicine suppository for treating chronic kidney failure, named Shenkangshuan suppository, and its preparation process. The medicine suppository is prepared with red sage, astragalus root and other medicine materials, and through soaking, decoction, filtering, concentration, adding ethanol, letting stand, filtering, recovering ethanol, adding matrix, molding and other steps. The present invention has the advantages of convenient rectum administration, no first pass effect in liver, no gastrointestinal reaction, high bioavailability, etc.
Description
The present invention relates to a kind of medicine for treating chronic kidney failure and preparation technology thereof who treats chronic renal failure.
Clinically mostly be to adopt oral medication with the treatment by Chinese herbs chronic renal failure at present, its weak point is to absorb slowly, and bioavailability is low, the course of treatment is long, and weak curative effect is especially poorer to the above curative effect of renal function injury moderate, and gastrointestinal reaction is bigger, unsuitable prolonged application.The Chinese medicine injection effect is rapid, the bioavailability height, short treating period, good effect especially has better effects to the patient more than the renal function injury moderate, and a patent " SHENKANG ZHUSHEYE and preparation technology thereof " (application number 96117626 notification numbers 1146358) of applying for as the applicant is to extract the Chinese medicine injection made from herbal mixture, its weak point is complicated process of preparation, cost height, and need hospitalization uses inconvenience to the chronic renal failure patient of need long-term prescription.The present invention is that the dosage form to the patent " SHENKANG ZHUSHEYE and preparation technology thereof " of the applicant application changes agent.
The object of the present invention is to provide a kind of SHENKANG ZHUSHEYE to be changed the preparation technology that agent becomes rectal suppository, this technology is simple, and cost is low, and is easy to use, is applicable to that the chronic renal failure patient of long-term prescription consolidates curative effect behind hospitalization.
The present invention extracts the suppository of making by Radix Et Rhizoma Rhei, Radix Salviae Miltiorrhizae, the Radix Astragali, Flos Carthami, and its raw material is made up of for 10～20 parts 10～20 parts of Radix Et Rhizoma Rhei, 10～20 parts of Radix Salviae Miltiorrhizaes, 40～70 parts of the Radixs Astragali, Flos Carthami.During preparation, earlier Radix Et Rhizoma Rhei, Radix Salviae Miltiorrhizae are added 5～10 times of amounts of water at every turn, soaked 30 minutes for the first time, decoct three times, boiled 30 minutes at every turn, filter, merging filtrate, be concentrated into temperature 80 ℃～95 ℃ relative densities 1.20～1.23, put coldly, add ethanol and make that to contain the alcohol amount be 60%～80%, stir, airtight leaving standstill 24 hours filters, and filtrate recycling ethanol is standby 70 ℃～90 ℃ relative densities 1.25～1.28 to temperature; The Radix Astragali, Flos Carthami adds 5～10 times of amounts of water at every turn, soaks 30 minutes for the first time, decocts three times, boiled 30 minutes at every turn, and filtered merging filtrate, be concentrated into temperature 80 ℃～95 ℃ relative densities 1.20～1.23, put coldly, add ethanol and make that to contain the alcohol amount be 60%～80%, stir, airtight leaving standstill 24 hours filters, filtrate recycling ethanol to temperature 70 ℃～90 ℃ relative densities 1.25～1.28, merge with last liquid, add water and be stirred to temperature, left standstill 24 hours, filter with two layers of gauze 30 ℃～50 ℃ relative densities 1.10～1.12, remove the resin-like thing, be concentrated into the thick paste shape, measure moisture content and be controlled at 16%～20%, weigh, seven parts of taking polyethylene glycols-6000 and Polyethylene Glycol-1000 are three parts in addition, make substrate in 80 ℃～90 ℃ heat fused mixings,, get 15～25 parts of mixed-matrixes by the displacement value calculating of measuring and calculating, be incorporated in the thick paste of 80 ℃～90 ℃ of thawings, equality of temperature heats abundant mixing, in the impouring suppository mold, puts cold while hot, take out, promptly.
The invention has the advantages that preparation technology is simple, low, the easy operating of cost, easy to use, be easy to carry, and the distal rectal administration, avoid oral drugs to pass through the first pass effect and the reaction of critically ill patient the intestines and stomach of liver, reduce effective ingredient and destroy, bioavailability has QI invigorating and consolidates than the oral medication height, the effect of dissipating stasis and purging turbidity is applicable to that the chronic renal failure patient of long-term prescription consolidates curative effect behind hospitalization.Modern study shows that medicine for treating chronic kidney failure can alleviate the carrying out property damage of the compensatory nephron of CRF rat and the carrying out property of renal function goes down, thereby delays the process of CRF, and does not have obvious toxic-side effects.Main result of study is as follows: (1) main pharmacodynamics pedant: add the method for eating adenine with excision 5/6 nephridial tissue and excision one side kidney, duplicate rat chronic renal failure (CRF) model respectively, all produce azotemia, anemia, hypoalbuminemia and the damage of excess of the kidney matter that carrying out property increases the weight of.(every day 24,16,4g crude drug/kg) are respectively to these two kinds continuous 5 weeks of rectally of dissimilar CRF models with medicine for treating chronic kidney failure.The result shows: medicine for treating chronic kidney failure has some improvement to the azotemia of CRF rat.With the model group comparison same period, the horizontal decrease to some degree of blood BUN, Cr, be reduced to significantly (P＜0.05) of high dose group BUN, Hb gos up to some extent simultaneously, and ALB slightly improves, and the kidney coefficient is not had obvious influence.The result of histopathologic examination, treatment group and model group rat are compared, and remarkable reduction that compensatory glomerule hypertrophy obviously alleviates, the glomerule stage is hardened, tubular ectasia, epithelial cell damage and interstitial fibrosis all obviously alleviate, and the epithelial cell reparation increases.Show that medicine for treating chronic kidney failure can alleviate the carrying out property damage of the compensatory nephron of CRF rat and the carrying out property of renal function goes down, thereby delay the process of CRF.In addition, medicine for treating chronic kidney failure still has immunological enhancement and improves the effect of hemorheological property, can significantly improve the non-specific phagocytic function and the tardy property of the inductive mice of the DNCB skin hypersensitivity of mononuclear phagocyte under the mouse immune inhibition situation; Significantly reduce whole blood viscosity, plasma viscosity and the erythrocyte aggregation of blood stasis due to qi deficiency rat.(2) acute toxicity and irritation test: medicine for treating chronic kidney failure (extractum) 75g crude drug/kg (be a clinical consumption per day 90 times) three rectum (with colon) administration in 4 hours respectively, perhaps with the method to rat rectum (with colon) successive administration 7 days, the overt toxicity reaction all do not occur, none is only dead; Rectum and colon do not see that local excitation reaction and histopathology change.(3) long term toxicity test: medicine for treating chronic kidney failure with every day 50g crude drug/kg and 25g crude drug/kg to the continuous rectum of rat (with colon) administration four months, its outward appearance sign, behavioral activity, body weight gain, routine blood test, liver, renal function and 12 kinds of organ coefficients all do not have obvious influence, and main organs and peritoneum, tail vein there is no tangible pathological tissue morphological change.3 weeks of drug withdrawal, do not find tardy property toxic reaction, only in the time of four months, a little medicine pigmentation occurs in the local renal tubules,convoluted epithelial cell for examination group part rat, but do not see that being deposited pigment epithelium cell has obvious damage, and obviously reduce after the drug withdrawal in administration.(4) clinical research: carried out " the clinical prerun of medicine for treating chronic kidney failure treatment chronic renal failure " August in January, 1991 to nineteen ninety-five through Chengdu TCM Universities Affiliated Hospital and observed 21 examples altogether, 8 weeks of the course of treatment, produce effects 6 examples as a result, obvious effective rate is 28.57%; Effective 10 examples, effective percentage are 47.62%, and total effective rate is 76.19%.Do not find in the clinical prerun process that medicine for treating chronic kidney failure has any untoward reaction and obvious toxic-side effects.After JIUYUE in 1999 obtained national SDA Clinical Researches of New Drugs on the 7th, adopt multicenter, the randomized controlled test is a group leader unit with Nanfang Hospital of No.1 Military Medical Univ., the collaborative Hunan Province academy of traditional Chinese medicine, Shanxi Institute of Traditional Chinese Medicine, Anhui Chinese Medicine College Affiliated Hospital, five families of Henan Province Affiliated Hospital of the college of traditional Chinese medicine carry out the II clinical trial phase, observe 200 examples altogether, the result shows: 1. medicine for treating chronic kidney failure curative effect: produce effects 37%, and effective 40%, total effective rate 77%; 2. traditional Chinese medical science disease: recovery from illness 4%, produce effects 38%, effective 38%, invalid 6%, total effective rate 94%.
With specific embodiment the present invention is elaborated below:
Embodiment 1:
During preparation, earlier 10 parts of Radix Et Rhizoma Rhei, Radix Salviae Miltiorrhizae are added 7 times of amounts of water for 10 parts at every turn, soaked 30 minutes for the first time, decoct three times, boiled 30 minutes at every turn, filter, merging filtrate, be concentrated into 90 ℃ of relative densities 1.20～1.23, put coldly, add ethanol and make that to contain the alcohol amount be 70%, stir, airtight leaving standstill 24 hours filters, and filtrate recycling ethanol to 80 ℃ relative density 1.25～1.28 is standby; 70 parts of the Radixs Astragali, Flos Carthami adds 7 times of amounts of water for 10 parts at every turn, soaks 30 minutes for the first time, decocts three times, boiled 30 minutes at every turn, and filtered merging filtrate, be concentrated into 90 ℃ of relative densities 1.20～1.23, put coldly, add ethanol and make that to contain the alcohol amount be 70%, stir, airtight leaving standstill 24 hours filters filtrate recycling ethanol to 80 ℃ relative density 1.25～1.28, merge with last liquid, add water and be stirred to 40 ℃ of relative densities 1.10～1.12, left standstill 24 hours, filter with two layers of gauze, remove the resin-like thing, be concentrated into the thick paste shape, measure moisture content and be controlled at 16%～20%, weigh, seven parts of taking polyethylene glycols-6000 and Polyethylene Glycol-1000 are three parts in addition, make substrate in 80 ℃～90 ℃ heat fused mixings,, get 20 parts of mixed-matrixes by the displacement value calculating of measuring and calculating, be incorporated in the thick paste of 80 ℃～90 ℃ of thawings, equality of temperature heats abundant mixing, in the impouring suppository mold, puts cold while hot, take out, promptly.
Embodiment 2:
During preparation, earlier 15 parts of Radix Et Rhizoma Rhei, Radix Salviae Miltiorrhizae are added 7 times of amounts of water for 15 parts at every turn, soaked 30 minutes for the first time, decoct three times, boiled 30 minutes at every turn, filter, merging filtrate, be concentrated into 85 ℃ of relative densities 1.20～1.23, put coldly, add ethanol and make that to contain the alcohol amount be 70%, stir, airtight leaving standstill 24 hours filters, and filtrate recycling ethanol to 75 ℃ relative density 1.25～1.28 is standby; 55 parts of the Radixs Astragali, Flos Carthami adds 7 times of amounts of water for 15 parts at every turn, soaks 30 minutes for the first time, decocts three times, boiled 30 minutes at every turn, and filtered merging filtrate, be concentrated into 85 ℃ of relative densities 1.20～1.23, put coldly, add ethanol and make that to contain the alcohol amount be 70%, stir, airtight leaving standstill 24 hours filters filtrate recycling ethanol to 75 ℃ relative density 1.25～1.28, merge with last liquid, add water and be stirred to 35 ℃ of relative densities 1.10～1.12, left standstill 24 hours, filter with two layers of gauze, remove the resin-like thing, be concentrated into the thick paste shape, measure moisture content and be controlled at 16%～20%, weigh, seven parts of taking polyethylene glycols-6000 and Polyethylene Glycol-1000 are three parts in addition, make substrate in 80 ℃～90 ℃ heat fused mixings,, get 20 parts of mixed-matrixes by the displacement value calculating of measuring and calculating, be incorporated in the thick paste of 80 ℃～90 ℃ of thawings, equality of temperature heats abundant mixing, in the impouring suppository mold, puts cold while hot, take out, promptly.
Embodiment 3:
During preparation, earlier 20 parts of Radix Et Rhizoma Rhei, Radix Salviae Miltiorrhizae are added 7 times of amounts of water for 20 parts at every turn, soaked 30 minutes for the first time, decoct three times, boiled 30 minutes at every turn, filter, merging filtrate, be concentrated into 95 ℃ of relative densities 1.20～1.23, put coldly, add ethanol and make that to contain the alcohol amount be 70%, stir, airtight leaving standstill 24 hours filters, and filtrate recycling ethanol to 80 ℃ relative density 1.25～1.28 is standby; 40 parts of the Radixs Astragali, Flos Carthami adds 7 times of amounts of water for 20 parts at every turn, soaks 30 minutes for the first time, decocts three times, boiled 30 minutes at every turn, and filtered merging filtrate, be concentrated into 95 ℃ of relative densities 1.20～1.23, put coldly, add ethanol and make that to contain the alcohol amount be 70%, stir, airtight leaving standstill 24 hours filters filtrate recycling ethanol to 80 ℃ relative density 1.25～1.28, merge with last liquid, add water and be stirred to 45 ℃ of relative densities 1.10～1.12, left standstill 24 hours, filter with two layers of gauze, remove the resin-like thing, be concentrated into the thick paste shape, measure moisture content and be controlled at 16%～20%, weigh, seven parts of taking polyethylene glycols-6000 and Polyethylene Glycol-1000 are three parts in addition, make substrate in 80 ℃～90 ℃ heat fused mixings,, get 20 parts of mixed-matrixes by the displacement value calculating of measuring and calculating, be incorporated in the thick paste of 80 ℃～90 ℃ of thawings, equality of temperature heats abundant mixing, in the impouring suppository mold, puts cold while hot, take out, promptly.
Claims (2)
1, a kind of medicine for treating chronic kidney failure for the treatment of chronic renal failure, its raw material is by 10～20 parts of Radix Et Rhizoma Rhei, 10～20 parts of Radix Salviae Miltiorrhizaes, 40～70 parts of the Radixs Astragali, 10～20 parts of compositions of Flos Carthami, it is characterized in that it is to make by following preparation technology: during preparation, earlier with Radix Et Rhizoma Rhei, Radix Salviae Miltiorrhizae adds 6～10 times of amounts of water at every turn, soaked 30 minutes for the first time, decoct three times, boiled 30 minutes at every turn, filter, merging filtrate, be concentrated into temperature 80 ℃～95 ℃ relative densities 1.20～1.23, put coldly, add ethanol and make that to contain the alcohol amount be 60%～80%, stir, airtight leaving standstill 24 hours filters, and filtrate recycling ethanol is standby 70 ℃～90 ℃ relative densities 1.25～1.28 to temperature; The Radix Astragali, Flos Carthami adds 6～10 times of amounts of water at every turn, soaks 30 minutes for the first time, decocts three times, boiled 30 minutes at every turn, and filtered merging filtrate, be concentrated into temperature 80 ℃～95 ℃ relative densities 1.20～1.23, put coldly, add ethanol and make that to contain the alcohol amount be 60%～70%, stir, airtight leaving standstill 24 hours filters, filtrate recycling ethanol to temperature 70 ℃～90 ℃ relative densities 1.25～1.28, merge with last liquid, add water and be stirred to temperature, left standstill 24 hours, filter with two layers of gauze 30 ℃～50 ℃ relative densities 1.10～1.12, remove the resin-like thing, be concentrated into the thick paste shape, measure moisture content and be controlled at 16%～20%, weigh, seven parts of taking polyethylene glycols-6000 and Polyethylene Glycol-1000 are three parts in addition, make substrate in 80 ℃～90 ℃ heat fused mixings,, get 15～25 parts of mixed-matrixes by the displacement value calculating of measuring and calculating, be incorporated in the thick paste of 80 ℃～90 ℃ of thawings, equality of temperature heats abundant mixing, in the impouring suppository mold, puts cold while hot, take out, promptly.
2, the preparation technology of medicine for treating chronic kidney failure as claimed in claim 1, when it is characterized in that preparing, earlier 10～20 parts of Radix Et Rhizoma Rhei, Radix Salviae Miltiorrhizae are added 6～10 times of amounts of water for 10～20 parts at every turn, soaked 30 minutes for the first time, decoct three times, boiled 30 minutes at every turn, filter, merging filtrate is concentrated into temperature 80 ℃～95 ℃ relative densities 1.20～1.23, put cold, add ethanol and make that to contain the alcohol amount be 60%～70%, stir airtight leaving standstill 24 hours, filter, filtrate recycling ethanol is standby 70～90 ℃ of relative densities 1.25～1.28 to temperature; 40～70 parts of the Radixs Astragali, Flos Carthami adds 6～10 times of amounts of water for 10～20 parts at every turn, soaks 30 minutes for the first time, decocts three times, boiled 30 minutes at every turn, and filtered merging filtrate, be concentrated into temperature 80 ℃～95 ℃ relative densities 1.20～1.23, put coldly, add ethanol and make that to contain the alcohol amount be 60%～70%, stir, airtight leaving standstill 24 hours filters, filtrate recycling ethanol to temperature 70 ℃～90 ℃ relative densities 1.25～1.28, merge with last liquid, add water and be stirred to temperature, left standstill 24 hours, filter with two layers of gauze 30 ℃～50 ℃ relative densities 1.10～1.12, remove the resin-like thing, be concentrated into the thick paste shape, measure moisture content and be controlled at 16%～20%, weigh, seven parts of taking polyethylene glycols-6000 and Polyethylene Glycol-1000 are three parts in addition, make substrate in 80 ℃～90 ℃ heat fused mixings,, get 15～25 parts of mixed-matrixes by the displacement value calculating of measuring and calculating, be incorporated in the thick paste of 80 ℃～90 ℃ of thawings, equality of temperature heats abundant mixing, in the impouring suppository mold, puts cold while hot, take out, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410039418XA CN100389794C (en) | 2004-02-11 | 2004-02-11 | Medicine for treating chronic kidney failure and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410039418XA CN100389794C (en) | 2004-02-11 | 2004-02-11 | Medicine for treating chronic kidney failure and its preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1654058A true CN1654058A (en) | 2005-08-17 |
| CN100389794C CN100389794C (en) | 2008-05-28 |
Family
ID=34892336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200410039418XA Expired - Lifetime CN100389794C (en) | 2004-02-11 | 2004-02-11 | Medicine for treating chronic kidney failure and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100389794C (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102475762A (en) * | 2010-11-30 | 2012-05-30 | 西安世纪盛康药业有限公司 | Shenkang oral liquid compound preparation for treating chronic renal failure and preparation method of Shenkang oral liquid compound preparation |
| CN102475760A (en) * | 2010-11-30 | 2012-05-30 | 西安世纪盛康药业有限公司 | Kidney-health compound preparation for treating chronic renal failure and preparation method thereof |
| CN102475761A (en) * | 2010-11-30 | 2012-05-30 | 西安世纪盛康药业有限公司 | Shenkang oral solid compound preparation for treating chronic renal failure and preparation method of Shenkang oral solid compound preparation |
| CN102475754A (en) * | 2010-11-30 | 2012-05-30 | 西安世纪盛康药业有限公司 | Shenkang soft capsule for treating chronic renal failure and preparation method of Shenkang soft capsule |
| CN102475758A (en) * | 2010-11-30 | 2012-05-30 | 西安世纪盛康药业有限公司 | Shenkang tablet for treating chronic renal failure and preparation method of Shenkang tablet |
| CN102475763A (en) * | 2010-11-30 | 2012-05-30 | 西安世纪盛康药业有限公司 | Shenkang dripping pill for treating chronic renal failure and preparation method thereof |
| CN102475756A (en) * | 2010-11-30 | 2012-05-30 | 西安世纪盛康药业有限公司 | Shenkang injection compound preparation for treating chronic renal failure and preparation method of Shenkang injection compound preparation |
| CN102475759A (en) * | 2010-11-30 | 2012-05-30 | 西安世纪盛康药业有限公司 | Shenkang sodium chloride injection for treating chronic renal failure and preparation method of Shenkang sodium chloride injection |
| CN102475757A (en) * | 2010-11-30 | 2012-05-30 | 西安世纪盛康药业有限公司 | Kidney-strengthening externally applied compound preparation for treating chronic renal failure and preparation method of compound preparation |
| CN102475755A (en) * | 2010-11-30 | 2012-05-30 | 西安世纪盛康药业有限公司 | Shenkang aerosol for treating chronic renal failure and preparation method of Shenkang aerosol |
| CN102475753A (en) * | 2010-11-30 | 2012-05-30 | 西安世纪盛康药业有限公司 | Kidney-health patch for treating chronic renal failure and preparation method thereof |
| CN102475764A (en) * | 2010-11-30 | 2012-05-30 | 西安世纪盛康药业有限公司 | Preparation method of Shenkang injection |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1154502C (en) * | 1996-07-16 | 2004-06-23 | 吴芳 | Shengkang injection solution (for nephrosis) and preparation technology |
-
2004
- 2004-02-11 CN CNB200410039418XA patent/CN100389794C/en not_active Expired - Lifetime
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102475762A (en) * | 2010-11-30 | 2012-05-30 | 西安世纪盛康药业有限公司 | Shenkang oral liquid compound preparation for treating chronic renal failure and preparation method of Shenkang oral liquid compound preparation |
| CN102475760A (en) * | 2010-11-30 | 2012-05-30 | 西安世纪盛康药业有限公司 | Kidney-health compound preparation for treating chronic renal failure and preparation method thereof |
| CN102475761A (en) * | 2010-11-30 | 2012-05-30 | 西安世纪盛康药业有限公司 | Shenkang oral solid compound preparation for treating chronic renal failure and preparation method of Shenkang oral solid compound preparation |
| CN102475754A (en) * | 2010-11-30 | 2012-05-30 | 西安世纪盛康药业有限公司 | Shenkang soft capsule for treating chronic renal failure and preparation method of Shenkang soft capsule |
| CN102475758A (en) * | 2010-11-30 | 2012-05-30 | 西安世纪盛康药业有限公司 | Shenkang tablet for treating chronic renal failure and preparation method of Shenkang tablet |
| CN102475763A (en) * | 2010-11-30 | 2012-05-30 | 西安世纪盛康药业有限公司 | Shenkang dripping pill for treating chronic renal failure and preparation method thereof |
| CN102475756A (en) * | 2010-11-30 | 2012-05-30 | 西安世纪盛康药业有限公司 | Shenkang injection compound preparation for treating chronic renal failure and preparation method of Shenkang injection compound preparation |
| CN102475759A (en) * | 2010-11-30 | 2012-05-30 | 西安世纪盛康药业有限公司 | Shenkang sodium chloride injection for treating chronic renal failure and preparation method of Shenkang sodium chloride injection |
| CN102475757A (en) * | 2010-11-30 | 2012-05-30 | 西安世纪盛康药业有限公司 | Kidney-strengthening externally applied compound preparation for treating chronic renal failure and preparation method of compound preparation |
| CN102475755A (en) * | 2010-11-30 | 2012-05-30 | 西安世纪盛康药业有限公司 | Shenkang aerosol for treating chronic renal failure and preparation method of Shenkang aerosol |
| CN102475753A (en) * | 2010-11-30 | 2012-05-30 | 西安世纪盛康药业有限公司 | Kidney-health patch for treating chronic renal failure and preparation method thereof |
| CN102475764A (en) * | 2010-11-30 | 2012-05-30 | 西安世纪盛康药业有限公司 | Preparation method of Shenkang injection |
| CN102475757B (en) * | 2010-11-30 | 2013-10-16 | 西安世纪盛康药业有限公司 | Kidney-strengthening externally applied compound preparation for treating chronic renal failure and preparation method of compound preparation |
| CN102475759B (en) * | 2010-11-30 | 2013-10-16 | 西安世纪盛康药业有限公司 | Shenkang sodium chloride injection for treating chronic renal failure and preparation method of Shenkang sodium chloride injection |
| CN102475763B (en) * | 2010-11-30 | 2013-12-04 | 西安世纪盛康药业有限公司 | Shenkang dripping pill for treating chronic renal failure and preparation method thereof |
| CN102475755B (en) * | 2010-11-30 | 2013-12-04 | 西安世纪盛康药业有限公司 | Shenkang aerosol for treating chronic renal failure and preparation method of Shenkang aerosol |
| CN102475761B (en) * | 2010-11-30 | 2013-12-18 | 西安世纪盛康药业有限公司 | Shenkang oral solid compound preparation for treating chronic renal failure and preparation method of Shenkang oral solid compound preparation |
| CN102475762B (en) * | 2010-11-30 | 2013-12-18 | 西安世纪盛康药业有限公司 | Shenkang oral liquid compound preparation for treating chronic renal failure and preparation method of Shenkang oral liquid compound preparation |
| CN102475754B (en) * | 2010-11-30 | 2013-12-18 | 西安世纪盛康药业有限公司 | Shenkang soft capsule for treating chronic renal failure and preparation method of Shenkang soft capsule |
| CN102475758B (en) * | 2010-11-30 | 2013-12-18 | 西安世纪盛康药业有限公司 | Shenkang tablet for treating chronic renal failure and preparation method of Shenkang tablet |
| CN102475756B (en) * | 2010-11-30 | 2014-03-19 | 西安世纪盛康药业有限公司 | Shenkang injection compound preparation for treating chronic renal failure and preparation method of Shenkang injection compound preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100389794C (en) | 2008-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101972338B (en) | Chinese medicinal preparation for treating infantile upper respiratory tract infection and preparation method thereof | |
| CN102973685B (en) | Anti-fatigue traditional Chinese medicine preparation and preparation method thereof | |
| CN102755594A (en) | Traditional Chinese medicine composition for treating acute and chronic hepatitis B and preparation method thereof | |
| CN100389794C (en) | Medicine for treating chronic kidney failure and its preparing process | |
| CN106237075A (en) | A kind of have resisting fatigue and promote the food of attention effect, health product or pharmaceutical composition and its production and use | |
| CN101249243B (en) | Chinese medicine for curing acute leukemia | |
| CN101085039B (en) | Composition for preventing and treating diabetes (hyperglycaemia) and its preparation method | |
| CN101366903B (en) | Traditional Chinese medicine composition for treating climacteric syndrome | |
| CN102698077A (en) | Traditional Chinese medicine composition for treating sub-health | |
| CN103110815B (en) | Traditional Chinese medicine composition for treating type II diabetes and preparation method thereof | |
| CN104083640A (en) | Traditional Chinese medicinal composition for treating diabetes mellitus and preparation method thereof | |
| CN103845607A (en) | Compound traditional Chinese medicinal preparation for preventing and treating diabetes mellitus and preparation method thereof | |
| CN102671118A (en) | Traditional Chinese medicine for treating diabetes mellitus and method for preparing same | |
| CN102784230B (en) | Pharmaceutical composition preparation for treating nutritional anemia | |
| CN103230018A (en) | Vitamin health-care capsule containing snake powder element | |
| CN103393938B (en) | Traditional Chinese medicine composition for reducing blood sugar | |
| CN106362005A (en) | Sugar-free anti-ageing oral liquid and preparing and taking method thereof | |
| CN102228596B (en) | Pharmaceutical composition and preparation and applications thereof in treating coronary heart disease and angina pectoris | |
| CN104436049A (en) | Traditional Chinese medicine composition for treating heart disease | |
| CN104547105A (en) | Agent for reducing blood glucose | |
| CN100542560C (en) | A kind of Chinese medicine and preparation technology thereof who treats chronic pelvic inflammatory disease | |
| CN101890145B (en) | Medicament for treating diabetes and preparation thereof | |
| CN103316106A (en) | Danshan fat reducing granules and preparation method thereof | |
| CN103055192B (en) | Women inflammation recovery chewable tablet | |
| CN101623338B (en) | Traditional Chinese medicine compound medicine for raising white blood cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: XI'AN CENTURY SHENGKANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: WU FANG Effective date: 20091002 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20091002 Address after: Shaanxi province Xi'an Fengjing Industrial Park Fengjing Road No. 6 Patentee after: XI'AN SHIJISHENGKANG PHARMACEUTICAL INDUSTRY Co.,Ltd. Address before: Shaanxi city of Xi'an province high tech Zone Tang Yan Road No. 35 room B2003 Mong modern city Patentee before: Wu Fang |
|
| CX01 | Expiry of patent term |
Granted publication date: 20080528 |
|
| CX01 | Expiry of patent term | ||
| DD01 | Delivery of document by public notice |
Addressee: Lv Yanying Document name: Notice of Termination of Patent Rights |
|
| DD01 | Delivery of document by public notice |